KORU Medical Systems (NASDAQ:KRMD) versus Bausch + Lomb (NYSE:BLCO) Financial Survey

KORU Medical Systems (NASDAQ:KRMD) and Bausch + Lomb (NYSE:BLCO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Earnings & Valuation

This table compares KORU Medical Systems and Bausch + Lomb”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KORU Medical Systems	N/A	N/A	N/A	($0.04)	-79.25
Bausch + Lomb	$5.32 billion	1.18	-$171.54 million	($0.48)	-36.67

KORU Medical Systems has higher earnings, but lower revenue than Bausch + Lomb. KORU Medical Systems is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for KORU Medical Systems and Bausch + Lomb, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KORU Medical Systems	1	0	4	1	2.83
Bausch + Lomb	1	7	6	1	2.47

KORU Medical Systems currently has a consensus target price of $7.00, indicating a potential upside of 120.82%. Bausch + Lomb has a consensus target price of $19.46, indicating a potential upside of 10.56%. Given KORU Medical Systems’ stronger consensus rating and higher probable upside, research analysts plainly believe KORU Medical Systems is more favorable than Bausch + Lomb.

Insider and Institutional Ownership

58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 18.5% of KORU Medical Systems shares are held by insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares KORU Medical Systems and Bausch + Lomb’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
KORU Medical Systems	N/A	N/A	N/A
Bausch + Lomb	N/A	N/A	N/A

Summary

KORU Medical Systems beats Bausch + Lomb on 5 of the 7 factors compared between the two stocks.

About KORU Medical Systems

KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.